Leptin levels in different forms of Chagas' disease

Fernandes, Fábio; Dantas, Simone Alves; Ianni, Bárbara Maria; Ramires, Felix José Alvarez; Buck, Paula; Salemi, Vera Maria Cury; Lopes, Heno Ferreira; Mady, Charles

doi:10.1590/s0100-879x2006005000152

Cited by 19 publications

(13 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussioncontrasting

confidence: 99%

“…At variance with our findings, some authors [21] reported decreased leptin levels in chagasic patients with congestive heart failure, whereas another study [44] showed no differences between CCC patients and controls. In both studies, however, the classification of myocardial involvement was different from the present one [21,44]. In line with our findings, leptin levels were found increased in non-chagasic individuals with chronic heart failure as a reflection of the proposed hypertrophic effects of leptin on cardiomyocytes [45,46].…”

Section: Discussioncontrasting

confidence: 99%

See 1 more Smart Citation

Dysregulated Network of Immune, Endocrine and Metabolic Markers is Associated to More Severe Human Chronic Chagas Cardiomyopathy

González

Villar

D’Attilio

et al. 2018

Neuroimmunomodulation

View full text Add to dashboard Cite

Individuals who are infected with Trypanosoma cruzi develop chronic Chagas cardiomyopathy (CCC), which is a complication involving a series of immune pathogenetic mechanisms, although an association between immune and metabolic alterations was more recently proposed. Accordingly, we investigated the immuno-metabolic response in chagasic patients and their possible influence on CCC pathogenesis. To this end, T. cruzi-seropositive (asymptomatic or with CCC) and sero-negative individuals were studied. Serum tumour necrosis factor (TNF)-α, interleukin (IL)-6, adipocytokines and the expression of their receptors in peripheral blood mononuclear cell (PBMC) were evaluated, together with other factors influencing the immune response. CCC patients showed major metabolic and hormonal abnormalities, in parallel with increased IL-6 and leptin serum levels. TNF-α receptor s, leptin and adiponectin receptors (ObR and Adipo-Rs respectively), as well as PPAR-γ expression in PBMCs from CCC patients were compatible with a counteracting response leading to an unfavourable immune-metabolic profile. These results suggest that persistently increased levels of immune-metabolic pro-inflammatory mediators along with the adverse endocrine anti-inflammatory response of CCC individuals, may contribute to the underlying mechanisms dealing with myocardial tissue damage.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussioncontrasting

confidence: 99%

Dysregulated Network of Immune, Endocrine and Metabolic Markers is Associated to More Severe Human Chronic Chagas Cardiomyopathy

González

Villar

D’Attilio

et al. 2018

Neuroimmunomodulation

View full text Add to dashboard Cite

show abstract

“…In particular, the concentration of BNP and ANP in serum were systematically studied as markers of heart damage in Chagasic patients (Garcia-Alvarez et al, 2010; Heringer-Walther et al, 2005; Ribeiro et al, 2002) since they had been previously related with cardiovascular diseases (Wang et al, 2006; Wondergem et al, 2001). Increased concentrations of BNP and ANP strongly correlated with the severity of Chagas-associated cardiac damage, being BNP more sensitive than ANP (Fernandes et al, 2007; Heringer-Walther et al, 2005; Talvani et al, 2004b). Upon these findings, the authors proposed that BNP could be measured periodically in asymptomatic patients as screening test to detect incipient ventricular dysfunction (Heringer-Walther et al, 2005).…”

Section: Diagnostic Applications For Chagas D Isease: Pending Issuesmentioning

confidence: 99%

Chagas Disease Diagnostic Applications

Balouz

Agüero

Buscaglia

2017

Advances in Parasitology

View full text Add to dashboard Cite

Chagas disease, caused by the protozoan Trypanosoma cruzi, is a life-long and debilitating illness of major significance throughout Latin America, and an emergent threat to global public health. Being a neglected disease, the vast majority of Chagasic patients have limited access to proper diagnosis and treatment, and there is only a marginal investment into R&D for drug and vaccine development. In this context, identification of novel biomarkers able to transcend the current limits of diagnostic methods surfaces as a main priority in Chagas disease applied research. The expectation is that these novel biomarkers will provide reliable, reproducible and accurate results irrespective of the genetic background, infecting parasite strain, stage of disease, and clinical-associated features of Chagasic populations. In addition, they should be able to address other still unmet diagnostic needs, including early detection of congenital T. cruzi transmission, rapid assessment of treatment efficiency or failure, indication/prediction of disease progression and direct parasite typification in clinical samples. The lack of access of poor and neglected populations to essential diagnostics also stress the necessity of developing new methods operational in Point-of-Care (PoC) settings. In summary, emergent diagnostic tests integrating these novel and tailored tools should provide a significant impact on the effectiveness of current intervention schemes and on the clinical management of Chagasic patients. In this chapter, we discuss the present knowledge and possible future steps in Chagas disease diagnostic applications, as well as the opportunity provided by recent advances in high-throughput methods for biomarker discovery.

show abstract

“…Biochemical molecules, such as glutamic oxaloacetic transaminase, glutamic-pyruvic transaminase, alkaline phosphatase, acid maltase, alpha-hydroxybutyric dehydrogenase (or LDH1), leptin, adipokines and angiotensin-converting enzyme, have also been tested in humans to assess early cardiological damage ( Alarcon-Corredor et al 2002 , Combs et al 2005 , Fernandes et al 2007 , Wang et al 2010 ). Nevertheless, there are no reports of studies using these biomarkers to assess therapeutic efficacy.…”

Section: Host Response/damage Biomarkersmentioning

confidence: 99%

Biomarkers of therapeutic responses in chronic Chagas disease: state of the art and future perspectives

Pinazo

Thomas²,

Bustamante

et al. 2015

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

The definition of a biomarker provided by the World Health Organization is any substance, structure, or process that can be measured in the body, or its products and influence, or predict the incidence or outcome of disease. Currently, the lack of prognosis and progression markers for chronic Chagas disease has posed limitations for testing new drugs to treat this neglected disease. Several molecules and techniques to detect biomarkers in Trypanosoma cruzi-infected patients have been proposed to assess whether specific treatment with benznidazole or nifurtimox is effective. Isolated proteins or protein groups from different T. cruzi stages and parasite-derived glycoproteins and synthetic neoglycoconjugates have been demonstrated to be useful for this purpose, as have nucleic acid amplification techniques. The amplification of T. cruzi DNA using the real-time polymerase chain reaction method is the leading test for assessing responses to treatment in a short period of time. Biochemical biomarkers have been tested early after specific treatment. Cytokines and surface markers represent promising molecules for the characterisation of host cellular responses, but need to be further assessed.

show abstract

Leptin levels in different forms of Chagas' disease

Abstract: Leptin is produced primarily by adipocytes. Although originally associated with the central regulation of satiety and energy metabolism, increasing evidence indicates that leptin may be an important mediator in cardiovascular pathophysiology.

Cited by 19 publications

References 19 publications

Dysregulated Network of Immune, Endocrine and Metabolic Markers is Associated to More Severe Human Chronic Chagas Cardiomyopathy

Dysregulated Network of Immune, Endocrine and Metabolic Markers is Associated to More Severe Human Chronic Chagas Cardiomyopathy

Chagas Disease Diagnostic Applications

Biomarkers of therapeutic responses in chronic Chagas disease: state of the art and future perspectives

Contact Info

Product

Resources

About